OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Lau on the Association of irAEs and OS in the HIMALAYA Study in HCC

June 28th 2023

George Lau, MD, FRCP, FAASLD, discusses the association between immune-related adverse effects and overall survival for patients with unresectable hepatocellular carcinoma enrolled on the phase 3 HIMALAYA trial.

Dr Paz-Ares on Tusamitamab Ravtansine in CEACAM5-Positive NSCLC

June 28th 2023

Luis Paz-Ares, MD, PhD, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial of tusamitamab ravtansine in patients with nonsquamous non–small cell lung cancer with CEACAM5 expression.

Dr Meric-Bernstam on the Investigation of CBX-12 in Advanced or Metastatic Solid Tumors

June 28th 2023

Funda Meric-Bernstam, MD, discusses a first-in-human phase 1/2 study of CBX-12 in patients with advanced or metastatic solid tumors.

Dr Fathi on Ziftomenib in R/R NPM1-Mutant AML

June 28th 2023

Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.

Dr Liu on the Use of PSMA PET to Inform Lymph Node Dissection in Prostate Cancer

June 28th 2023

Jen-Jane Liu, MD, discusses how prostate-specific membrane antigen PET imaging may help inform lymph node dissection in the localized disease setting for patients with prostate cancer.

Dr Choueiri on the Investigation of ICI Continuation in Advanced RCC

June 28th 2023

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.

Dr Wilky on the Study of Zalifrelimab, Balstilimab, and Doxorubicin in Soft Tissue Sarcoma

June 27th 2023

Breelyn A. Wilky, MD, discusses the rationale for investigating the combination of zalifrelimab, balstilimab, and doxorubicin in patients with advanced/metastatic soft tissue sarcoma, and early results from a phase 2 trial.

Dr Reed on the Investigation of Trastuzumab Deruxtecan in HER2+ Osteosarcoma

June 27th 2023

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

Dr Murray on the Investigation of Prognostic Markers in Cemiplimab-treated NSCLC

June 27th 2023

Joseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.

Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in Myelofibrosis

June 27th 2023

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Dr Gupta on the MAIN-CAV Trial of Maintenance Cabozantinib Plus Avelumab in mUC

June 27th 2023

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Dr. Barata sobre el Ensayo EMBARK en Pacientes con Cáncer de Próstata no Metastásico de alto Riesgo y Sensible a Hormonas.

June 26th 2023

Pedro Barata, MD, MSc, discusses the importance of the phase 3 EMBARK trial in patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Dr. Barata sobre las Necesidades no Cubiertas de los Pacientes con Cáncer de Próstata

June 26th 2023

Pedro Barata, MD, MSc, discusses remaining unmet needs for patients with prostate cancer.

Dr Monga on the Investigation of PRT811 in High-Grade Glioma or Uveal Melanoma

June 26th 2023

Varun Monga, MD, discusses the investigation of the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes

June 26th 2023

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Dr Montesinos on Quizartinib Plus Chemotherapy in Newly Diagnosed FLT3-ITD Wild-Type AML

June 26th 2023

Pau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

June 26th 2023

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Dr Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC

June 26th 2023

Nicholas Coupe, MBBS, PhD, discusses the investigation of IMM60 plus pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer.

Combinación de Ribociclib y Terapia Endocrina en Pacientes con Cáncer de Mama Temprano, Positivo a Receptores Hormonales y Negativo a HER2

June 26th 2023

Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.

Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NEC

June 23rd 2023

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.